{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T23:26:45Z","timestamp":1789082805783,"version":"build-2803163510"},"reference-count":46,"publisher":"American Association of Psychiatric Pharmacists (AAPP)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n        <jats:p>Parkinson disease (PD) is a common neurodegenerative disorder in older adults characterized by motor and nonmotor symptoms and complications. Impulse control disorders (ICDs), such as pathological gambling, compulsive shopping, compulsive sexual behavior (hypersexuality), and binge eating disorder, affect 13.6% of the PD population. Use of dopamine receptor agonists (DRAs) is considered a major risk factor for ICD development. Amantadine and a high dose of levodopa were linked to ICDs to a lesser extent than DRAs. Based on the severity of behavior(s), ICDs can negatively impact social, professional, and familial lives of patients and their families. Ideally, all PD patients taking DRAs, high doses of levodopa, and\/or amantadine should be routinely asked about or monitored for ICDs during therapy initiation and continuation. Dose decrease or withdrawal of the offending agent, primarily DRAs, is usually the most effective first step in ICD management. Careful dose adjustment with close monitoring is warranted due to risk for worsening of motor symptoms or emergence of dopamine agonist withdrawal syndrome (DAWS). About 1\/3 of PD patients with ICD who decrease or discontinue DRA experienced DAWS. The lowest dose of DRA will need to be continued to balance ICDs and DAWS as it is not alleviated by other dopaminergic or psychotropic medications. Other therapies with low empiric evidence, such as amantadine, naloxone, cognitive behavior therapy, deep brain stimulation, and psychopharmacotherapy showed mixed results for ICD management. It is crucial that clinicians are familiar with the psychiatric complications of PD, including ICDs, beyond mere recognition and management of motor symptoms.<\/jats:p>","DOI":"10.9740\/mhc.2016.09.229","type":"journal-article","created":{"date-parts":[[2016,8,31]],"date-time":"2016-08-31T17:29:54Z","timestamp":1472664594000},"page":"229-235","source":"Crossref","is-referenced-by-count":11,"title":["Introduction to Parkinson disease (PD) and its complications"],"prefix":"10.9740","volume":"6","author":[{"given":"Marketa","family":"Marvanova","sequence":"first","affiliation":[{"name":"(Corresponding author) Chair and Associate Professor, Pharmacy Practice Department, College of Health Professions, North Dakota State University, Fargo, North Dakota, marketa.marvanova@ndsu.edu"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4719","reference":[{"issue":"6","key":"i2168-9709-6-5-229-b01","series-title":"Lancet Neurol","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/S1474-4422(06)70471-9","article-title":"Epidemiology of Parkinson's disease","volume":"5","author":"de Lau \n              LML,","year":"2006","unstructured":"de Lau \n              LML, \n            \n            \n              Breteler \n              MMB. \n            \n          \n          Epidemiology of Parkinson's disease. Lancet Neurol. 2006;5(6):525-35. DOI: 10.1016\/S1474-4422(06)70471-9. PubMed PMID: 16713924."},{"issue":"1","key":"i2168-9709-6-5-229-b02","series-title":"Neurohospitalist","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1177\/1941874411427734","article-title":"Inpatient management of Parkinson disease: Current challenges and future directions","volume":"2","author":"Oguh \n              O,","year":"2012","unstructured":"Oguh \n              O, \n            \n            \n              Videnovic \n              A. \n            \n          \n          Inpatient management of Parkinson disease: Current challenges and future directions. Neurohospitalist. 2012;2(1):28-35. DOI: 10.1177\/1941874411427734. PubMed PMID: 23983860."},{"issue":"Suppl 10","key":"i2168-9709-6-5-229-b03","series-title":"Trends Neurosci","first-page":"S8","article-title":"Pathophysiology of the basal ganglia in Parkinson's disease","volume":"23","author":"Obeso \n              JA,","year":"2000","unstructured":"Obeso \n              JA, \n            \n            \n              Rodr\u00edguez-Oroz \n              MC, \n            \n            \n              Rodr\u00edguez \n              M, \n            \n            \n              Lanciego \n              JL, \n            \n            \n              Artieda \n              J, \n            \n            \n              Gonzalo \n              N, \n            \n            et al. \n          Pathophysiology of the basal ganglia in Parkinson's disease. Trends Neurosci. 2000;23Suppl 10:S8-19."},{"issue":"1","key":"i2168-9709-6-5-229-b04","series-title":"Psychosomatics","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S0033-3182(00)71169-8","article-title":"Neuropsychiatric aspects of Parkinson's disease","volume":"41","author":"Marsh \n              L.","year":"2000","unstructured":"Marsh \n              L. \n            \n          \n          Neuropsychiatric aspects of Parkinson's disease. Psychosomatics. 2000;41(1):15-23. DOI: 10.1016\/S0033-3182(00)71169-8. PubMed PMID: 10665264."},{"issue":"Suppl 5","key":"i2168-9709-6-5-229-b05","series-title":"J Neurol","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1007\/s00415-008-5010-5","article-title":"Parkinson's disease-related disorders in the impulsive-compulsive spectrum","volume":"255","author":"Wolters \n              EC,","year":"2008","unstructured":"Wolters \n              EC, \n            \n            \n              van der Werf \n              YD, \n            \n            \n              van den Heuvel \n              OA. \n            \n          \n          Parkinson's disease-related disorders in the impulsive-compulsive spectrum. J Neurol. 2008;255Suppl 5:48-56. DOI: 10.1007\/s00415-008-5010-5. PubMed PMID: 18787882."},{"issue":"2","key":"i2168-9709-6-5-229-b06","series-title":"Mov Disord","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/mds.26016","article-title":"Clinical spectrum of impulse control disorders in Parkinson's disease","volume":"30","author":"Weintraub \n              D,","year":"2015","unstructured":"Weintraub \n              D, \n            \n            \n              David \n              AS, \n            \n            \n              Evans \n              AH, \n            \n            \n              Grant \n              JE, \n            \n            \n              Stacy \n              M. \n            \n          \n          Clinical spectrum of impulse control disorders in Parkinson's disease. Mov Disord. 2015;30(2):121-7. DOI: 10.1002\/mds.26016. PubMed PMID: 25370355."},{"issue":"Suppl 2","key":"i2168-9709-6-5-229-b07","series-title":"Ann Neurol","doi-asserted-by":"publisher","first-page":"S93","DOI":"10.1002\/ana.21454","article-title":"Dopamine and impulse control disorders in Parkinson's disease","volume":"64","author":"Weintraub \n              D.","year":"2009","unstructured":"Weintraub \n              D. \n            \n          \n          Dopamine and impulse control disorders in Parkinson's disease. Ann Neurol. 2009;64Suppl 2:S93-100. DOI: 10.1002\/ana.21454. PubMed PMID: 19127573."},{"issue":"5","key":"i2168-9709-6-5-229-b08","series-title":"Arch Neurol","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1001\/archneurol.2010.65","article-title":"Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients","volume":"67","author":"Weintraub \n              D,","year":"2010","unstructured":"Weintraub \n              D, \n            \n            \n              Koester \n              J, \n            \n            \n              Potenza \n              MN, \n            \n            \n              Siderowf \n              AD, \n            \n            \n              Stacy \n              M, \n            \n            \n              Voon \n              V, \n            \n            et al. \n          Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol. 2010;67(5):589-95. DOI: 10.1001\/archneurol.2010.65. PubMed PMID: 20457959."},{"issue":"4","key":"i2168-9709-6-5-229-b09","series-title":"J Neurol Neurosurg Psychiatry","first-page":"423","article-title":"Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies","volume":"68","author":"Giovannoni \n              G,","year":"2000","unstructured":"Giovannoni \n              G, \n            \n            \n              O'Sullivan \n              JD, \n            \n            \n              Turner \n              K, \n            \n            \n              Manson \n              AJ, \n            \n            \n              Lees \n              AJ. \n            \n          \n          Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry. 2000;68(4):423-8. PubMed PMID: 10727476."},{"issue":"1","key":"i2168-9709-6-5-229-b10","series-title":"Mov Disord","first-page":"90","article-title":"Behavioral effects of levodopa","volume":"30","author":"Beaulieu-Boire \n              I,","year":"2015","unstructured":"Beaulieu-Boire \n              I, \n            \n            \n              Lang \n              AE. \n            \n          \n          Behavioral effects of levodopa. Mov Disord. 2015Jan;30(1):90-102."},{"issue":"6","key":"i2168-9709-6-5-229-b11","series-title":"Ann Neurol","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1002\/ana.22356","article-title":"Impulse control disorders in Parkinson disease: a multicenter case-control study","volume":"69","author":"Voon \n              V,","year":"2011","unstructured":"Voon \n              V, \n            \n            \n              Sohr \n              M, \n            \n            \n              Lang \n              AE, \n            \n            \n              Potenza \n              MN, \n            \n            \n              Siderowf \n              AD, \n            \n            \n              Whetteckey \n              J, \n            \n            et al. \n          Impulse control disorders in Parkinson disease: a multicenter case-control study. Ann Neurol. 2011;69(6):986-96. DOI: 10.1002\/ana.22356. PubMed PMID: 21416496."},{"issue":"3","key":"i2168-9709-6-5-229-b12","series-title":"Mov Disord","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1002\/mds.25291","article-title":"Prospective cohort study of impulse control disorders in Parkinson's disease","volume":"28","author":"Bastiaens \n              J,","year":"2013","unstructured":"Bastiaens \n              J, \n            \n            \n              Dorfman \n              BJ, \n            \n            \n              Christos \n              PJ, \n            \n            \n              Nirenberg \n              MJ. \n            \n          \n          Prospective cohort study of impulse control disorders in Parkinson's disease. Mov Disord. 2013;28(3):327-33. DOI: 10.1002\/mds.25291. PubMed PMID: 23283708."},{"issue":"7","key":"i2168-9709-6-5-229-b13","series-title":"Arch Neurol","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1001\/archneur.63.7.969","article-title":"Association of dopamine agonist use with impulse control disorders in Parkinson disease","volume":"63","author":"Weintraub \n              D,","year":"2006","unstructured":"Weintraub \n              D, \n            \n            \n              Siderowf \n              AD, \n            \n            \n              Potenza \n              MN, \n            \n            \n              Goveas \n              J, \n            \n            \n              Morales \n              KH, \n            \n            \n              Duda \n              JE, \n            \n            et al. \n          Association of dopamine agonist use with impulse control disorders in Parkinson disease. Arch Neurol. 2006;63(7):969-73. DOI: 10.1001\/archneur.63.7.969. PubMed PMID: 16831966."},{"issue":"2","key":"i2168-9709-6-5-229-b14","series-title":"Arch Neurol","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1001\/archneur.64.2.212","article-title":"Factors associated with dopaminergic drug-related pathological gambling in Parkinson disease","volume":"64","author":"Voon \n              V,","year":"2007","unstructured":"Voon \n              V, \n            \n            \n              Thomsen \n              T, \n            \n            \n              Miyasaki \n              JM, \n            \n            \n              de Souza \n              M, \n            \n            \n              Shafro \n              A, \n            \n            \n              Fox \n              SH, \n            \n            et al. \n          Factors associated with dopaminergic drug-related pathological gambling in Parkinson disease. Arch Neurol. 2007;64(2):212-6. DOI: 10.1001\/archneur.64.2.212. PubMed PMID: 17296836."},{"issue":"3","key":"i2168-9709-6-5-229-b15","series-title":"Neurology","first-page":"422","article-title":"Pathological gambling associated with dopamine agonist therapy in Parkinson's disease","volume":"61","author":"Driver-Dunckley \n              E,","year":"2003","unstructured":"Driver-Dunckley \n              E, \n            \n            \n              Samanta \n              J, \n            \n            \n              Stacy \n              M. \n            \n          \n          Pathological gambling associated with dopamine agonist therapy in Parkinson's disease. Neurology. 2003;61(3):422-3. PubMed PMID: 12913220."},{"issue":"9","key":"i2168-9709-6-5-229-b16","series-title":"Arch Neurol","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1001\/archneur.62.9.noc50009","article-title":"Pathological gambling caused by drugs used to treat Parkinson disease","volume":"62","author":"Dodd \n              ML,","year":"2005","unstructured":"Dodd \n              ML, \n            \n            \n              Klos \n              KJ, \n            \n            \n              Bower \n              JH, \n            \n            \n              Geda \n              YE, \n            \n            \n              Josephs \n              KA, \n            \n            \n              Ahlskog \n              JE. \n            \n          \n          Pathological gambling caused by drugs used to treat Parkinson disease. Arch Neurol. 2005;62(9):1377-81. DOI: 10.1001\/archneur.62.9.noc50009. PubMed PMID: 16009751."},{"issue":"6","key":"i2168-9709-6-5-229-b17","series-title":"Parkinsonism Relat Disord","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.parkreldis.2005.06.005","article-title":"Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson's disease and multiple system atrophy","volume":"11","author":"Klos \n              KJ,","year":"2005","unstructured":"Klos \n              KJ, \n            \n            \n              Bower \n              JH, \n            \n            \n              Josephs \n              KA, \n            \n            \n              Matsumoto \n              JY, \n            \n            \n              Ahlskog \n              JE. \n            \n          \n          Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson's disease and multiple system atrophy. Parkinsonism Relat Disord. 2005;11(6):381-6. DOI: 10.1016\/j.parkreldis.2005.06.005. PubMed PMID: 16109498."},{"issue":"12","key":"i2168-9709-6-5-229-b18","series-title":"Mov Disord","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1002\/mds.21110","article-title":"Problematic gambling on dopamine agonists: Not such a rarity","volume":"21","author":"Grosset \n              KA,","year":"2006","unstructured":"Grosset \n              KA, \n            \n            \n              Macphee \n              G, \n            \n            \n              Pal \n              G, \n            \n            \n              Stewart \n              D, \n            \n            \n              Watt \n              A, \n            \n            \n              Davie \n              J, \n            \n            et al. \n          Problematic gambling on dopamine agonists: Not such a rarity. Mov Disord. 2006;21(12):2206-8. DOI: 10.1002\/mds.21110. PubMed PMID: 17013907."},{"issue":"1","key":"i2168-9709-6-5-229-b19","series-title":"Physiol Behav","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.physbeh.2011.04.055","article-title":"Pathological behaviors provoked by dopamine agonist therapy of Parkinson's disease","volume":"104","author":"Ahlskog \n              JE.","year":"2011","unstructured":"Ahlskog \n              JE. \n            \n          \n          Pathological behaviors provoked by dopamine agonist therapy of Parkinson's disease. Physiol Behav. 2011;104(1):168-72. DOI: 10.1016\/j.physbeh.2011.04.055. PubMed PMID: 21557955."},{"issue":"11","key":"i2168-9709-6-5-229-b20","series-title":"Neurology","first-page":"1750","article-title":"Prospective prevalence of pathological gambling and medication association in Parkinson disease","volume":"66","author":"Voon \n              V,","year":"2006","unstructured":"Voon \n              V, \n            \n            \n              Hassan \n              K, \n            \n            \n              Zurowski \n              M, \n            \n            \n              Duff-Canning \n              S, \n            \n            \n              de Souza \n              M, \n            \n            \n              Fox \n              S, \n            \n            et al. \n          Prospective prevalence of pathological gambling and medication association in Parkinson disease. Neurology. 2006;66(11):1750-2. PubMed PMID: 16769956."},{"issue":"6","key":"i2168-9709-6-5-229-b21","series-title":"Ann Neurol","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1002\/ana.22164","article-title":"Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study","volume":"68","author":"Weintraub \n              D,","year":"2010","unstructured":"Weintraub \n              D, \n            \n            \n              Sohr \n              M, \n            \n            \n              Potenza \n              MN, \n            \n            \n              Siderowf \n              AD, \n            \n            \n              Stacy \n              M, \n            \n            \n              Voon \n              V, \n            \n            et al. \n          Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study. Ann Neurol. 2010;68(6):963-8. DOI: 10.1002\/ana.22164. PubMed PMID: 21154480."},{"issue":"2","key":"i2168-9709-6-5-229-b22","series-title":"Mov Disord","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1002\/mds.23964","article-title":"Multiple impulse control disorders developing in Parkinson's disease after initiation of amantadine","volume":"27","author":"Walsh \n              RA,","year":"2012","unstructured":"Walsh \n              RA, \n            \n            \n              Lang \n              AE. \n            \n          \n          Multiple impulse control disorders developing in Parkinson's disease after initiation of amantadine. Mov Disord. 2012;27(2):326. DOI: 10.1002\/mds.23964. PubMed PMID: 21954056."},{"issue":"2","key":"i2168-9709-6-5-229-b23","series-title":"Neurology","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1212\/WNL.0b013e31827b915c","article-title":"Screening for impulse control symptoms in patients with de novo Parkinson disease: a case-control study","volume":"80","author":"Weintraub \n              D,","year":"2013","unstructured":"Weintraub \n              D, \n            \n            \n              Papay \n              K, \n            \n            \n              Siderowf \n              A. \n            \n          \n          Screening for impulse control symptoms in patients with de novo Parkinson disease: a case-control study. Neurology. 2013;80(2):176-80. DOI: 10.1212\/WNL.0b013e31827b915c. PubMed PMID: 23296128."},{"issue":"10","key":"i2168-9709-6-5-229-b24","series-title":"Mov Disord","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1002\/mds.22571","article-title":"Validation of the questionnaire for impulsive-compulsive disorders in Parkinson's disease","volume":"24","author":"Weintraub \n              D,","year":"2009","unstructured":"Weintraub \n              D, \n            \n            \n              Hoops \n              S, \n            \n            \n              Shea \n              JA, \n            \n            \n              Lyons \n              KE, \n            \n            \n              Pahwa \n              R, \n            \n            \n              Driver-Dunckley \n              ED, \n            \n            et al. \n          Validation of the questionnaire for impulsive-compulsive disorders in Parkinson's disease. Mov Disord. 2009;24(10):1461-7. DOI: 10.1002\/mds.22571. PubMed PMID: 19452562."},{"issue":"8","key":"i2168-9709-6-5-229-b25","series-title":"J Neurol Neurosurg Psychiatry","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1136\/jnnp-2013-306787","article-title":"Impulse control disorder in patients with Parkinson's disease under dopamine agonist therapy: a multicentre study","volume":"85","author":"Garcia-Ruiz \n              PJ,","year":"2014","unstructured":"Garcia-Ruiz \n              PJ, \n            \n            \n              Martinez Castrillo \n              JC, \n            \n            \n              Alonso-Canovas \n              A, \n            \n            \n              Herranz Barcenas \n              A, \n            \n            \n              Vela \n              L, \n            \n            \n              Sanchez Alonso \n              P, \n            \n            et al. \n          Impulse control disorder in patients with Parkinson's disease under dopamine agonist therapy: a multicentre study. J Neurol Neurosurg Psychiatry. 2014;85(8):840-4. DOI: 10.1136\/jnnp-2013-306787. PubMed PMID: 24434037."},{"issue":"7","key":"i2168-9709-6-5-229-b26","series-title":"Int J Neurosci","doi-asserted-by":"publisher","first-page":"503","DOI":"10.3109\/00207454.2013.768243","article-title":"Factors associated with the development of impulse compulsive disorders in Parkinson patients","volume":"123","author":"Rana \n              AQ,","year":"2013","unstructured":"Rana \n              AQ, \n            \n            \n              Mansoor \n              W, \n            \n            \n              Hussaini \n              S, \n            \n            \n              Al Mosabbir \n              A, \n            \n            \n              Rahman \n              M, \n            \n            \n              Rahman \n              L. \n            \n          \n          Factors associated with the development of impulse compulsive disorders in Parkinson patients. Int J Neurosci. 2013;123(7):503-6. DOI: 10.3109\/00207454.2013.768243. PubMed PMID: 23336737."},{"issue":"3","key":"i2168-9709-6-5-229-b27","series-title":"Mov Disord","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1002\/mds.21872","article-title":"The relationship between impulsivity and impulse control disorders in Parkinson's disease","volume":"23","author":"Isaias \n              IU,","year":"2008","unstructured":"Isaias \n              IU, \n            \n            \n              Siri \n              C, \n            \n            \n              Cilia \n              R, \n            \n            \n              De Gaspari \n              D, \n            \n            \n              Pezzoli \n              G, \n            \n            \n              Antonini \n              A. \n            \n          \n          The relationship between impulsivity and impulse control disorders in Parkinson's disease. Mov Disord. 2008;23(3):411-5. DOI: 10.1002\/mds.21872. PubMed PMID: 18067187."},{"issue":"1","key":"i2168-9709-6-5-229-b28","series-title":"Physiol Behav","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.physbeh.2011.04.055","article-title":"Pathological behaviors provoked by dopamine agonist therapy of Parkinson's disease","volume":"104","author":"Ahlskog \n              JE.","year":"2011","unstructured":"Ahlskog \n              JE. \n            \n          \n          Pathological behaviors provoked by dopamine agonist therapy of Parkinson's disease. Physiol Behav. 2011;104(1):168-72. DOI: 10.1016\/j.physbeh.2011.04.055. PubMed PMID: 21557955."},{"issue":"2","key":"i2168-9709-6-5-229-b29","series-title":"Int J Geriatr Psychiatry","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1002\/gps.2704","article-title":"Carer burden in apathy and impulse control disorders in Parkinson's disease","volume":"27","author":"Leroi \n              I,","year":"2012","unstructured":"Leroi \n              I, \n            \n            \n              Harbishettar \n              V, \n            \n            \n              Andrews \n              M, \n            \n            \n              McDonald \n              K, \n            \n            \n              Byrne \n              EJ, \n            \n            \n              Burns \n              A. \n            \n          \n          Carer burden in apathy and impulse control disorders in Parkinson's disease. Int J Geriatr Psychiatry. 2012;27(2):160-6. DOI: 10.1002\/gps.2704. PubMed PMID: 21462269."},{"issue":"1","key":"i2168-9709-6-5-229-b30","series-title":"J Clin Neurosci","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jocn.2013.02.032","article-title":"Effect of impulse control disorders on disability and quality of life in Parkinson's disease patients","volume":"21","author":"Phu \n              AL,","year":"2014","unstructured":"Phu \n              AL, \n            \n            \n              Xu \n              Z, \n            \n            \n              Brakoulias \n              V, \n            \n            \n              Mahant \n              N, \n            \n            \n              Fung \n              VSC, \n            \n            \n              Moore \n              GD, \n            \n            et al. \n          Effect of impulse control disorders on disability and quality of life in Parkinson's disease patients. J Clin Neurosci. 2014;21(1):63-6. DOI: 10.1016\/j.jocn.2013.02.032. PubMed PMID: 24035421."},{"key":"i2168-9709-6-5-229-b31","series-title":"Health Qual Life Outcomes","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s12955-015-0281-x","article-title":"Health-related quality of life in Parkinson's disease: a cross-sectional study focusing on non-motor symptoms","volume":"13","author":"Kadastik-Eerme \n              L,","year":"2015","unstructured":"Kadastik-Eerme \n              L, \n            \n            \n              Rosenthal \n              M, \n            \n            \n              Paju \n              T, \n            \n            \n              Muldmaa \n              M, \n            \n            \n              Taba \n              P. \n            \n          \n          Health-related quality of life in Parkinson's disease: a cross-sectional study focusing on non-motor symptoms. Health Qual Life Outcomes. 2015;13:83. DOI: 10.1186\/s12955-015-0281-x. PubMed PMID: 26088201."},{"issue":"4","key":"i2168-9709-6-5-229-b32","series-title":"Eur J Neurol","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1111\/ene.12646","article-title":"Impulse control disorders in Parkinson's disease: don't set your mind at rest by self-assessments","volume":"22","author":"Baumann-Vogel \n              H,","year":"2015","unstructured":"Baumann-Vogel \n              H, \n            \n            \n              Valko \n              PO, \n            \n            \n              Eisele \n              G, \n            \n            \n              Baumann \n              CR. \n            \n          \n          Impulse control disorders in Parkinson's disease: don't set your mind at rest by self-assessments. Eur J Neurol. 2015;22(4):603-9. DOI: 10.1111\/ene.12646. PubMed PMID: 25598147."},{"issue":"1","key":"i2168-9709-6-5-229-b33","series-title":"Mov Disord","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/mds.21770","article-title":"Long-term follow-up of impulse control disorders in Parkinson's disease","volume":"23","author":"Mamikonyan \n              E,","year":"2008","unstructured":"Mamikonyan \n              E, \n            \n            \n              Siderowf \n              AD, \n            \n            \n              Duda \n              JE, \n            \n            \n              Potenza \n              MN, \n            \n            \n              Horn \n              S, \n            \n            \n              Stern \n              MB, \n            \n            et al. \n          Long-term follow-up of impulse control disorders in Parkinson's disease. Mov Disord. 2008;23(1):75-80. DOI: 10.1002\/mds.21770. PubMed PMID: 17960796."},{"issue":"2","key":"i2168-9709-6-5-229-b34","series-title":"Mov Disord","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1002\/mds.26099","article-title":"Management of impulse control disorders in Parkinson's disease: controversies and future approaches","volume":"30","author":"Samuel \n              M,","year":"2015","unstructured":"Samuel \n              M, \n            \n            \n              Rodriguez-Oroz \n              M, \n            \n            \n              Antonini \n              A, \n            \n            \n              Brotchie \n              JM, \n            \n            \n              Chaudhuri \n              KR, \n            \n            \n              Brown \n              RG, \n            \n            et al. \n          Management of impulse control disorders in Parkinson's disease: controversies and future approaches. Mov Disord. 2015;30(2):150-9. DOI: 10.1002\/mds.26099. PubMed PMID: 25607799."},{"issue":"1","key":"i2168-9709-6-5-229-b35","series-title":"Arch Neurol","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1001\/archneurol.2009.294","article-title":"Dopamine agonist withdrawal syndrome in Parkinson disease","volume":"67","author":"Rabinak \n              CA,","year":"2010","unstructured":"Rabinak \n              CA, \n            \n            \n              Nirenberg \n              MJ. \n            \n          \n          Dopamine agonist withdrawal syndrome in Parkinson disease. Arch Neurol. 2010;67(1):58-63. DOI: 10.1001\/archneurol.2009.294. PubMed PMID: 20065130."},{"issue":"4","key":"i2168-9709-6-5-229-b36","series-title":"Prog Neurol Psychiat","first-page":"4","article-title":"Managing dopamine agonist withdrawal syndrome in Parkinson's disease","volume":"15","author":"Lindahl \n              AJ,","year":"2011","unstructured":"Lindahl \n              AJ, \n            \n            \n              MacMahon \n              DG. \n            \n          \n          Managing dopamine agonist withdrawal syndrome in Parkinson's disease. Prog Neurol Psychiat. 2011;15(4):4."},{"issue":"2","key":"i2168-9709-6-5-229-b37","series-title":"J Neurol Neurosurg Psychiatry","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1136\/jnnp-2012-302684","article-title":"Clinical features of dopamine agonist withdrawal syndrome in a movement disorders clinic","volume":"84","author":"Pondal \n              M,","year":"2013","unstructured":"Pondal \n              M, \n            \n            \n              Marras \n              C, \n            \n            \n              Miyasaki \n              J, \n            \n            \n              Moro \n              E, \n            \n            \n              Armstrong \n              MJ, \n            \n            \n              Strafella \n              AP, \n            \n            et al. \n          Clinical features of dopamine agonist withdrawal syndrome in a movement disorders clinic. J Neurol Neurosurg Psychiatry. 2013;84(2):130-5. DOI: 10.1136\/jnnp-2012-302684. PubMed PMID: 22933817."},{"issue":"3","key":"i2168-9709-6-5-229-b38","series-title":"Ann Neurol","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1002\/ana.22029","article-title":"Pathological gambling in Parkinson disease is reduced by amantadine","volume":"68","author":"Thomas \n              A,","year":"2010","unstructured":"Thomas \n              A, \n            \n            \n              Bonanni \n              L, \n            \n            \n              Gambi \n              F, \n            \n            \n              Di Iorio \n              A, \n            \n            \n              Onofrj \n              M. \n            \n          \n          Pathological gambling in Parkinson disease is reduced by amantadine. Ann Neurol. 2010;68(3):400-4. DOI: 10.1002\/ana.22029. PubMed PMID: 20687121."},{"issue":"9","key":"i2168-9709-6-5-229-b39","series-title":"Neurology","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1212\/WNL.0000000000000729","article-title":"Naltrexone for impulse control disorders in Parkinson disease: a placebo-controlled study","volume":"83","author":"Papay \n              K,","year":"2014","unstructured":"Papay \n              K, \n            \n            \n              Xie \n              SX, \n            \n            \n              Stern \n              M, \n            \n            \n              Hurtig \n              H, \n            \n            \n              Siderowf \n              A, \n            \n            \n              Duda \n              JE, \n            \n            et al. \n          Naltrexone for impulse control disorders in Parkinson disease: a placebo-controlled study. Neurology. 2014;83(9):826-33. DOI: 10.1212\/WNL.0000000000000729. PubMed PMID: 25037206."},{"issue":"6","key":"i2168-9709-6-5-229-b40","series-title":"Eur Addict Res","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1159\/000337442","article-title":"Cognitive-behavioral therapy for pathological gambling in Parkinson's disease: a pilot controlled study","volume":"18","author":"Jim\u00e9nez-Murcia \n              S,","year":"2012","unstructured":"Jim\u00e9nez-Murcia \n              S, \n            \n            \n              Bove \n              FI, \n            \n            \n              Israel \n              M, \n            \n            \n              Steiger \n              H, \n            \n            \n              Fern\u00e1ndez-Aranda \n              F, \n            \n            \n              Alvarez-Moya \n              E, \n            \n            et al. \n          Cognitive-behavioral therapy for pathological gambling in Parkinson's disease: a pilot controlled study. Eur Addict Res. 2012;18(6):265-74. DOI: 10.1159\/000337442. PubMed PMID: 22760081."},{"issue":"9","key":"i2168-9709-6-5-229-b41","series-title":"Neurology","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1212\/WNL.0b013e3182840678","article-title":"Trial of CBT for impulse control behaviors affecting Parkinson patients and their caregivers","volume":"80","author":"Okai \n              D,","year":"2013","unstructured":"Okai \n              D, \n            \n            \n              Askey-Jones \n              S, \n            \n            \n              Samuel \n              M, \n            \n            \n              O'Sullivan \n              SS, \n            \n            \n              Chaudhuri \n              KR, \n            \n            \n              Martin \n              A, \n            \n            et al. \n          Trial of CBT for impulse control behaviors affecting Parkinson patients and their caregivers. Neurology. 2013;80(9):792-9. DOI: 10.1212\/WNL.0b013e3182840678. PubMed PMID: 23325911."},{"issue":"14","key":"i2168-9709-6-5-229-b42","series-title":"Mov Disord","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1002\/mds.25636","article-title":"Levodopa infusion improves impulsivity and dopamine dysregulation syndrome in Parkinson's disease","volume":"28","author":"Catal\u00e1n \n              MJ,","year":"2013","unstructured":"Catal\u00e1n \n              MJ, \n            \n            \n              de Pablo-Fern\u00e1ndez \n              E, \n            \n            \n              Villanueva \n              C, \n            \n            \n              Fern\u00e1ndez-Diez \n              S, \n            \n            \n              Lape\u00f1a-Montero \n              T, \n            \n            \n              Garc\u00eda-Ramos \n              R, \n            \n            et al. \n          Levodopa infusion improves impulsivity and dopamine dysregulation syndrome in Parkinson's disease. Mov Disord. 2013;28(14):2007-10. DOI: 10.1002\/mds.25636. PubMed PMID: 24123193."},{"issue":"11","key":"i2168-9709-6-5-229-b43","series-title":"Mov Disord","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1002\/mds.21098","article-title":"Pathological gambling in Parkinson's disease improves on chronic subthalamic nucleus stimulation","volume":"21","author":"Ardouin \n              C,","year":"2006","unstructured":"Ardouin \n              C, \n            \n            \n              Voon \n              V, \n            \n            \n              Worbe \n              Y, \n            \n            \n              Abouazar \n              N, \n            \n            \n              Czernecki \n              V, \n            \n            \n              Hosseini \n              H, \n            \n            et al. \n          Pathological gambling in Parkinson's disease improves on chronic subthalamic nucleus stimulation. Mov Disord. 2006;21(11):1941-6. DOI: 10.1002\/mds.21098. PubMed PMID: 16972268."},{"issue":"Pt 5","key":"i2168-9709-6-5-229-b44","series-title":"Brain","first-page":"1463","article-title":"Subthalamic stimulation in Parkinson's disease: restoring the balance of motivated behaviours","volume":"135","author":"Lhomm\u00e9e \n              E,","year":"2012","unstructured":"Lhomm\u00e9e \n              E, \n            \n            \n              Klinger \n              H, \n            \n            \n              Thobois \n              S, \n            \n            \n              Schmitt \n              E, \n            \n            \n              Ardouin \n              C, \n            \n            \n              Bichon \n              A, \n            \n            et al. \n          Subthalamic stimulation in Parkinson's disease: restoring the balance of motivated behaviours. Brain. 2012;135(Pt 5):1463-77."},{"issue":"6","key":"i2168-9709-6-5-229-b45","series-title":"Parkinsonism Relat Disord","first-page":"413","article-title":"Impulse control and related disorders in Parkinson's disease patients treated with bilateral subthalamic nucleus stimulation: a review","volume":"17","author":"Broen \n              M,","year":"2011","unstructured":"Broen \n              M, \n            \n            \n              Duits \n              A, \n            \n            \n              Visser-Vandewalle \n              V, \n            \n            \n              Temel \n              Y, \n            \n            \n              Winogrodzka \n              A. \n            \n          \n          Impulse control and related disorders in Parkinson's disease patients treated with bilateral subthalamic nucleus stimulation: a review. Parkinsonism Relat Disord. 2011;17(6):413-7."},{"issue":"1","key":"i2168-9709-6-5-229-b46","series-title":"Plos One","doi-asserted-by":"publisher","first-page":"e29768","DOI":"10.1371\/journal.pone.0029768","article-title":"Effects of STN and GPi deep brain stimulation on impulse control disorders and dopamine dysregulation syndrome","volume":"7","author":"Moum \n              SJ,","year":"2012","unstructured":"Moum \n              SJ, \n            \n            \n              Price \n              CC, \n            \n            \n              Limotai \n              N, \n            \n            \n              Oyama \n              G, \n            \n            \n              Ward \n              H, \n            \n            \n              Jacobson \n              C, \n            \n            et al. \n          Effects of STN and GPi deep brain stimulation on impulse control disorders and dopamine dysregulation syndrome. Plos One. 2012;7(1):e29768. DOI: 10.1371\/journal.pone.0029768. PubMed PMID: 22295068."}],"container-title":["Mental Health Clinician"],"original-title":[],"link":[{"URL":"https:\/\/mhc.kglmeridian.com\/view\/journals\/mhcl\/6\/5\/article-p229.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/meridian.allenpress.com\/mhc\/article-pdf\/6\/5\/229\/2095484\/mhc_2016_09_229.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/mhc.kglmeridian.com\/downloadpdf\/journals\/mhcl\/6\/5\/article-p229.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/mhc.kglmeridian.com\/downloadpdf\/journals\/mhcl\/6\/5\/article-p229.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T00:37:00Z","timestamp":1732063020000},"score":1,"resource":{"primary":{"URL":"https:\/\/mhc.kglmeridian.com\/view\/journals\/mhcl\/6\/5\/article-p229.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":46,"journal-issue":{"issue":"5"},"URL":"https:\/\/doi.org\/10.9740\/mhc.2016.09.229","relation":{},"ISSN":["2168-9709"],"issn-type":[{"value":"2168-9709","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9]]}}}